Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 2
1987 2
1988 7
1989 14
1990 23
1991 20
1992 25
1993 26
1994 28
1995 55
1996 27
1997 46
1998 45
1999 52
2000 57
2001 75
2002 69
2003 95
2004 93
2005 102
2006 87
2007 92
2008 103
2009 102
2010 104
2011 106
2012 91
2013 101
2014 93
2015 82
2016 63
2017 66
2018 43
2019 37
2020 26
2021 30
2022 35
2023 19
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

1,969 results

Results by year

Filters applied: . Clear all
Page 1
Simvastatin and oxidative stress in humans: A randomized, double-blinded, placebo-controlled clinical trial.
Rasmussen ST, Andersen JT, Nielsen TK, Cejvanovic V, Petersen KM, Henriksen T, Weimann A, Lykkesfeldt J, Poulsen HE. Rasmussen ST, et al. Redox Biol. 2016 Oct;9:32-38. doi: 10.1016/j.redox.2016.05.007. Epub 2016 May 30. Redox Biol. 2016. PMID: 27281490 Free PMC article. Clinical Trial.
Therefore, we hypothesized that simvastatin may reduce oxidative stress in humans in vivo. We conducted a randomized, double-blinded, placebo-controlled study in which subjects were treated with either 40mg of simvastatin or placebo for 14 days. ...A total of 40 par …
Therefore, we hypothesized that simvastatin may reduce oxidative stress in humans in vivo. We conducted a randomized, double-blinded, …
Simvastatin Improves Neutrophil Function and Clinical Outcomes in Pneumonia. A Pilot Randomized Controlled Clinical Trial.
Sapey E, Patel JM, Greenwood H, Walton GM, Grudzinska F, Parekh D, Mahida RY, Dancer RCA, Lugg ST, Howells PA, Hazeldine J, Newby P, Scott A, Nightingale P, Hill AT, Thickett DR. Sapey E, et al. Am J Respir Crit Care Med. 2019 Nov 15;200(10):1282-1293. doi: 10.1164/rccm.201812-2328OC. Am J Respir Crit Care Med. 2019. PMID: 31206313 Free PMC article. Clinical Trial.
A post hoc analysis demonstrated that simvastatin therapy was associated with improved hospitalization-free survival compared with placebo. Simvastatin was well tolerated in this elderly and multimorbid patient group with common coprescription of macrolide antibioti …
A post hoc analysis demonstrated that simvastatin therapy was associated with improved hospitalization-free survival compared with pl …
Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease: A Randomized Clinical Trial.
Stevens KN, Creanor S, Jeffery A, Whone A, Zajicek J, Foggo A, Jones B, Chapman R, Cocking L, Wilks J, Webb D, Carroll C; PD STAT Study Group. Stevens KN, et al. JAMA Neurol. 2022 Dec 1;79(12):1232-1241. doi: 10.1001/jamaneurol.2022.3718. JAMA Neurol. 2022. PMID: 36315128 Free PMC article. Clinical Trial.
In the simvastatin arm, participants entered a 1-month phase of simvastatin, 40 mg daily, followed by 23 months of simvastatin, 80 mg daily, before a 2-month washout period. ...A total of 37 serious adverse events (AEs), including 3 deaths, and 171 AEs were r …
In the simvastatin arm, participants entered a 1-month phase of simvastatin, 40 mg daily, followed by 23 months of simvasta …
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis.
Pose E, Solà E, Lozano JJ, Juanola A, Sidorova J, Zaccherini G, de Wit K, Uschner F, Tonon M, Kazankov K, Jiménez C, Campion D, Napoleone L, Ma AT, Carol M, Morales-Ruiz M, Alessandria C, Beuers U, Caraceni P, Francoz C, Durand F, Mookerjee RP, Trebicka J, Vargas V, Piano S, Watson H, Abraldes JG, Kamath PS, Davis MM, Ginès P; investigators of the LIVERHOPE Consortium. Pose E, et al. Hepatol Commun. 2022 May;6(5):1100-1112. doi: 10.1002/hep4.1881. Epub 2021 Dec 28. Hepatol Commun. 2022. PMID: 34964311 Free PMC article. Clinical Trial.
An ACLF-specific signature was identified. Treatment with simvastatin and rifaximin was associated with changes in 161 of 985 metabolites in comparison to treatment with placebo. ...Notably, 18 of the 32 metabolites of the ACLF signature were affected by the treatment. Con …
An ACLF-specific signature was identified. Treatment with simvastatin and rifaximin was associated with changes in 161 of 985 metabol …
Effect of locally applied simvastatin on clinical attachment level and alveolar bone in periodontal maintenance patients: A randomized clinical trial.
Killeen AC, Krell LE, Bertels M, Christiansen MM, Anderson L, Hattervig RL, Samson KK, Wang D, Reinhardt RA. Killeen AC, et al. J Periodontol. 2022 Nov;93(11):1682-1690. doi: 10.1002/JPER.21-0708. Epub 2022 Jul 12. J Periodontol. 2022. PMID: 35622060 Free PMC article. Clinical Trial.
BACKGROUND: The purpose of this double-masked, randomized, controlled trial was to determine if the local application of simvastatin (SIM), combined with minimally invasive papilla reflection and root planing (PR/RP), is effective in improving clinical attachment level (CA …
BACKGROUND: The purpose of this double-masked, randomized, controlled trial was to determine if the local application of simvastatin …
A phase II clinical trial of the Safety Of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex.
Krymskaya VP, Courtwright AM, Fleck V, Dorgan D, Kotloff R, McCormack FX, Kreider M. Krymskaya VP, et al. Respir Med. 2020 Mar;163:105898. doi: 10.1016/j.rmed.2020.105898. Epub 2020 Feb 8. Respir Med. 2020. PMID: 32125970 Free article. Clinical Trial.
No patients withdrew or had a reduction in simvastatin dose because of adverse events. Two patients required sirolumus dose reduction for supratherapeutic trough levels following simvastatin initiation. ...The addition of simvastatin, however, was associated …
No patients withdrew or had a reduction in simvastatin dose because of adverse events. Two patients required sirolumus dose reduction …
The SEAS Trial.
Carabello BA. Carabello BA. Curr Cardiol Rep. 2010 Mar;12(2):122-4. doi: 10.1007/s11886-010-0094-9. Curr Cardiol Rep. 2010. PMID: 20425166 Clinical Trial.
The SEAS trial compared the effects of the combination of simvastatin and ezetimibe to placebo in retarding the progression of aortic stenosis (AS) and was the largest randomized trial of such therapies. ...
The SEAS trial compared the effects of the combination of simvastatin and ezetimibe to placebo in retarding the progression of aortic …
Effects of Ezetimibe/Simvastatin and Rosuvastatin on Oxidative Stress in Diabetic Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Villegas-Rivera G, Román-Pintos LM, Cardona-Muñoz EG, Arias-Carvajal O, Rodríguez-Carrizalez AD, Troyo-Sanromán R, Pacheco-Moisés FP, Moreno-Ulloa A, Miranda-Díaz AG. Villegas-Rivera G, et al. Oxid Med Cell Longev. 2015;2015:756294. doi: 10.1155/2015/756294. Epub 2015 Jul 28. Oxid Med Cell Longev. 2015. PMID: 26290682 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the effects of ezetimibe/simvastatin (EZE/SIMV) and rosuvastatin (ROSUV) on oxidative stress (OS) markers in patients with diabetic polyneuropathy (DPN). ...
OBJECTIVE: To evaluate the effects of ezetimibe/simvastatin (EZE/SIMV) and rosuvastatin (ROSUV) on oxidative stress (OS) markers in p …
A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors.
Cash T, Jonus HC, Tsvetkova M, Beumer JH, Sadanand A, Lee JY, Henry CJ, Aguilera D, Harvey RD, Goldsmith KC. Cash T, et al. Pediatr Blood Cancer. 2023 Aug;70(8):e30405. doi: 10.1002/pbc.30405. Epub 2023 May 9. Pediatr Blood Cancer. 2023. PMID: 37158620 Free PMC article. Clinical Trial.
METHODS: Simvastatin was administered orally twice daily on days 1-21, with topotecan and cyclophosphamide intravenously on days 1-5 of a 21-day cycle. ...CONCLUSIONS: The MTD of simvastatin with topotecan and cyclophosphamide was determined to be 100 mg/m(2) /dose. …
METHODS: Simvastatin was administered orally twice daily on days 1-21, with topotecan and cyclophosphamide intravenously on days 1-5 …
A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents.
Ogungbenro K, Wagner JB, Abdel-Rahman S, Leeder JS, Galetin A. Ogungbenro K, et al. Eur J Clin Pharmacol. 2019 Sep;75(9):1227-1235. doi: 10.1007/s00228-019-02697-y. Epub 2019 Jun 6. Eur J Clin Pharmacol. 2019. PMID: 31172248 Free PMC article. Clinical Trial.
The model confirmed the statistically significant effect of c.521T>C (rs4149056) on the pharmacokinetics of the active metabolite simvastatin acid in children/adolescents, consistent with adult data. In addition, age was identified as a covariate affecting elimination c …
The model confirmed the statistically significant effect of c.521T>C (rs4149056) on the pharmacokinetics of the active metabolite simv …
1,969 results